Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAEAN: Probiotics, Amikacin, or Vaccination for COPD Exacerbation
NCT03449459Phase 1Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Nanoparticles, Split/Subunit Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Lactobacillus rhamnosus GG, amikacin liposome inhalation suspension, influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Time to the first COPD exacerbation at 15 months. Started Dec 2018; status: completed.
02
Drugs
Lactobacillus rhamnosus GGamikacin liposome inhalation suspensioninfluenza vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03449459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03449459.